Beta

Spruce biosciences, inc.SPRB.US Overview

US StockHealthcare
(No presentation for SPRB)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

SPRB AI Insights

SPRB Overall Performance

SPRB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SPRB Recent Performance

-4.21%

Spruce biosciences, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

SPRB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check SPRB's Trend

SPRB Key Information

SPRB Valuation Metrics

SPRB Profile

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Price of SPRB

SPRB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SPRB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-28.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
49.19
PB Ratio
3.46
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-6869.30%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-28.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
49.19
PB Ratio
3.46
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-6869.30%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SPRB's latest earnings report released?

    The most recent financial report for Spruce biosciences, inc. (SPRB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SPRB's short-term business performance and financial health. For the latest updates on SPRB's earnings releases, visit this page regularly.

  • How is SPRB's revenue growth?

    In the latest financial report, Spruce biosciences, inc. (SPRB) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does SPRB have?

    At the end of the period, Spruce biosciences, inc. (SPRB) held Total Cash and Cash Equivalents of 48.91M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SPRB's EPS continuing to grow?

    According to the past four quarterly reports, Spruce biosciences, inc. (SPRB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -9.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SPRB?

    Spruce biosciences, inc. (SPRB)'s Free Cash Flow (FCF) for the period is -6.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 68.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SPRB?

    The latest valuation data shows Spruce biosciences, inc. (SPRB) has a Price-To-Earnings (PE) ratio of -2.19 and a Price/Earnings-To-Growth (PEG) ratio of 0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.